Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of this postmarketing surveillance is to obtain further information about the
tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic
obstructive respiratory tract disease under conditions of daily practice
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol Fenoterol, ipratropium drug combination Ipratropium